A Phase 2 interventional study of arformoterol and levalbuterol in Asthma, sponsored by Sumitomo Pharma America, Inc.. Completed at 14 sites in United States. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-02-22.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.
Among the 86 studies testing formoterol in Asthma, this one is the 56th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2008, is one of 17 in phase 2, and was the 29th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 85 interventional studies. Of the 76 that completed or were terminated, 29 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 86 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
16 studies in Asthma by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 3 (19%) have results posted.
Among the 16 studies in Asthma by Sumitomo Pharma Co., Ltd., this one is the 11th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 5th registered.
Sumitomo Pharma Co., Ltd.’s Asthma studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 86 studies testing formoterol in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 16 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the safety and tolerability of Arformoterol Tartrate in children with asthma
A randomized, double-blind two-way crossover study of three cumulative doses of arformoterol (7.5 ug per nebulization) and levalbuterol (0.63 mg per nebulization) given over a one hour period, followed by a single open-label treatment day with three cumulative doses of arformoterol 15 ug in subjects 2-11 years of age with asthma. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization. Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization.
Drug: arformoterol · Drug: levalbuterol
Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization. Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization.
Drug: arformoterol · Drug: levalbuterol
Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Also known as: Brovana
Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Also known as: Xopenex
Mean Heart Rate
Heart rate measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Time frame: predose, various timeframes up to 5 hours post last dose
Change From Predose in Mean Heart Rate
Heart rate measured at various timepoints minus the heart rate at predose.
Time frame: predose, various timeframes up to 5 hours post last dose
Mean Systolic Blood Pressure
Systolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Time frame: predose, various timeframes up to 5 hours post last dose
Change From Predose in Mean Systolic Blood Pressure
Mean systolic blood pressure measured at various timepoints minus the mean systolic blood pressure at predose
Time frame: predose, various timeframes up to 5 hours post last dose
Mean Diastolic Blood Pressure
Diastolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Time frame: predose, various timeframes up to 5 hours post last dose
Change From Predose in Mean Diastolic Blood Pressure
Mean diastolic blood pressure measured at various timepoints minus the predose diastolic blood pressure
Time frame: predose, various timeframes up to 5 hours post last dose
Mean Serum Potassium Levels
Time frame: Predose, 2 hours and 6 hours postdose 1
Change From Predose in Mean Serum Potassium
Change in mean serum potassium at the specified timepoint minus the predose value.
Time frame: predose, 2 and 6 hours post dose
Mean Serum Glucose Values
Time frame: Predose, 2 and 6 hours post dose 1
Change From Predose in Mean Serum Glucose
Change in mean serum glucose at the specified timepoint minus the predose value.
Time frame: predose, 2 and 6 hours post dose
Mean Forced Expiratory Volume in One Second(FEV1)
Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer.
Time frame: predose, various postdose times
Change From Predose of Mean Forced Expiratory Volume in One Second (FEV1)
Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer. Change in FEV1 was calculated as postdose value minus the predose value at each visit.
Time frame: predose, various postdose timepoints
Mean Peak Expiratory Flow Rate (PEFR)
PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters.
Time frame: predose, various postdose times
Change From Predose in Mean Peak Expiratory Flow Rate (PEFR)
PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters. Change in PEFR was calculated as postdose value minus the predose value at each visit.
Time frame: predose, various postdose times
Plasma Concentration of (R,R) Formoterol
If the mean plasma concentration was 'below the limit of quantification' (BLQ) which was set as \<=0.5 picograms/milliliter, the value is displayed as a zero.
Time frame: predose, various postdose times
| Milestone | ARF/LEV | LEV/ARF |
|---|---|---|
| Started | 27 | 26 |
| Completed | 22 | 24 |
| Not completed | 5 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Did not meet-no longer met entry criteri | 0 | 1 |
| Withdrew: Other | 1 | 1 |
| Milestone | ARF/LEV | LEV/ARF |
|---|---|---|
| Started | 22 | 24 |
| Completed | 22 | 24 |
| Not completed | 0 | 0 |
| Milestone | ARF/LEV | LEV/ARF |
|---|---|---|
| Started | 22 | 24 |
| Completed | 22 | 24 |
| Not completed | 0 | 0 |
Heart rate measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
| beats per minute | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| Predose (n=51,52,40) | 87.6 ± 12.56 | 84.7 ± 14.11 | 87.0 ± 17.47 |
| 15 min post dose 1 (n=51,52,40) | 89.3 ± 15.57 | 85.2 ± 15.19 | 89.4 ± 16.88 |
| 30 min post dose 1 (n=51,52,40) | 90.9 ± 14.47 | 86.6 ± 14.63 | 89.5 ± 15.59 |
| 60 min post dose 1 (n=51,51,40) | 96.4 ± 12.33 | 89.0 ± 13.67 | 93.5 ± 16.41 |
| 15 min post dose 2 (n=50,51,40) | 95.4 ± 12.94 | 87.5 ± 14.88 | 92.5 ± 18.60 |
| 30 min post dose 2 (n=47,50,40) | 97.1 ± 13.28 | 88.9 ± 13.33 | 93.3 ± 16.72 |
| 60 min post dose 2 (n=46,50,37) | 100.4 ± 16.60 | 89.3 ± 13.97 | 96.1 ± 12.80 |
| 30 min post last dose (n=49,52,40) | 99.2 ± 17.38 | 90.3 ± 14.24 | 96.1 ± 13.92 |
| 60 min post last dose (n=49,52,40) | 96.0 ± 16.45 | 93.3 ± 13.06 | 97.1 ± 14.95 |
| 1.5 hours post last dose (n=48,52,40) | 96.2 ± 17.29 | 91.8 ± 11.75 | 95.3 ± 16.42 |
| 2 hours post last dose (n=50,52,40) | 93.0 ± 16.23 | 91.2 ± 11.77 | 95.9 ± 14.57 |
| 2.5 hours post last dose (n=49,52,40) | 94.1 ± 16.22 | 90.2 ± 14.61 | 94.8 ± 15.66 |
| 3 hours post last dose (n=50,52,40) | 94.1 ± 14.84 | 90.6 ± 13.57 | 93.4 ± 16.04 |
| 3.5 hours post last dose (n=50,52,40) | 93.3 ± 14.65 | 89.8 ± 13.20 | 95.0 ± 15.16 |
| 4 hours post last dose (n=50,52,40) | 94.0 ± 12.68 | 89.3 ± 11.76 | 94.5 ± 14.94 |
| 4.5 hours post last dose (n=50,52,40) | 93.3 ± 13.71 | 89.6 ± 12.50 | 93.9 ± 16.49 |
| 5 hours post last dose (n=50,51,40) | 92.4 ± 15.36 | 89.8 ± 14.16 | 92.9 ± 14.51 |
Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer.
| liters | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| predose (n=37,38,27) | 1.554 ± 0.374 | 1.552 ± 0.377 | 1.486 ± 0.294 |
| 10 minutes post dose 1 (n=37,38,27) | 1.714 ± 0.411 | 1.668 ± 0.403 | 1.620 ± 0.315 |
| 25 minutes post dose 1 (n=37,37,27) | 1.712 ± 0.425 | 1.695 ± 0.409 | 1.644 ± 0.334 |
| 10 minutes post dose 2 (n=36,38,27) | 1.741 ± 0.430 | 1.721 ± 0.420 | 1.661 ± 0.332 |
| 25 minutes post dose 2 (n=36,38,27) | 1.735 ± 0.438 | 1.714 ± 0.423 | 1.669 ± 0.331 |
| 10 minutes post dose 3 (n=34,38,27) | 1.775 ± 0.402 | 1.731 ± 0.419 | 1.689 ± 0.340 |
| 25 minutes post dose 3 (n=35,38,26) | 1.782 ± 0.415 | 1.740 ± 0.419 | 1.700 ± 0.345 |
| 2 hours post dose 1 (n=36,37,27) | 1.784 ± 0.397 | 1.754 ± 0.408 | 1.704 ± 0.337 |
| 4 hours post dose 1 (n=36,38,27) | 1.732 ± 0.401 | 1.722 ± 0.423 | 1.684 ± 0.344 |
| 6 hours post dose 1 (n=36,38,27) | 1.667 ± 0.400 | 1.725 ± 0.426 | 1.660 ± 0.356 |
Heart rate measured at various timepoints minus the heart rate at predose.
| beats per minute | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| 15 min post dose 1 (n=51,52,40) | 1.6 ± 10.27 | 0.5 ± 9.40 | 2.3 ± 10.33 |
| 30 min post dose 1 (n=51,52,40) | 3.2 ± 11.91 | 2.0 ± 11.06 | 2.5 ± 11.14 |
| 60 min post dose 1 (n=51,51,40) | 8.7 ± 10.70 | 4.4 ± 11.85 | 6.5 ± 12.62 |
| 15 min post dose 2 (n=50,51,40) | 7.8 ± 10.72 | 2.8 ± 11.48 | 5.5 ± 12.89 |
| 30 min post dose 2 (n=47,50,40) | 10.0 ± 10.67 | 4.5 ± 10.46 | 6.3 ± 12.90 |
| 60 min post dose 2 (n=46,50,37) | 13.2 ± 13.81 | 4.7 ± 10.50 | 9.5 ± 12.89 |
| 30 min post last dose (n=49,52,40) | 11.9 ± 14.11 | 5.6 ± 11.44 | 9.0 ± 13.34 |
| 60 min post last dose (n=49,52,40) | 8.7 ± 13.97 | 8.6 ± 14.06 | 10.0 ± 14.81 |
| 1.5 hours post last dose (n=48,52,40) | 8.9 ± 11.73 | 7.1 ± 12.65 | 8.3 ± 15.95 |
| 2 hours post last dose (n=50,52,40) | 5.6 ± 12.13 | 6.6 ± 10.77 | 8.9 ± 12.69 |
| 2.5 hours post last dose (n=49,52,40) | 6.8 ± 11.20 | 5.5 ± 14.33 | 7.8 ± 13.36 |
| 3 hours post last dose (n=50,52,40) | 6.7 ± 10.94 | 5.9 ± 12.74 | 6.4 ± 13.31 |
| 3.5 hours post last dose (n=50,52,40) | 5.9 ± 11.89 | 5.1 ± 11.63 | 7.9 ± 12.11 |
| 4 hours post last dose (n=50,52,40) | 6.6 ± 10.30 | 4.6 ± 13.51 | 7.4 ± 11.62 |
| 4.5 hours post last dose (n=50,52,40) | 5.9 ± 10.86 | 4.9 ± 12.00 | 6.9 ± 12.70 |
| 5 hours post last dose (n=50,51,40) | 5.0 ± 12.03 | 5.3 ± 12.41 | 5.8 ± 12.55 |
Systolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
| mmHg | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| Predose (n=51,52,40) | 102.1 ± 10.80 | 101.5 ± 9.86 | 100.6 ± 10.36 |
| 15 min post dose 1 (n=51,52,40) | 102.9 ± 10.90 | 101.2 ± 11.07 | 102.6 ± 11.42 |
| 30 min post dose 1 (n=51,52,40) | 104.6 ± 12.08 | 102.5 ± 10.20 | 100.3 ± 9.78 |
| 60 min post dose 1 (n=51,51,40) | 105.8 ± 9.31 | 102.7 ± 9.82 | 103.2 ± 10.82 |
| 15 min post dose 2 (n=50,51,40) | 105.0 ± 11.20 | 101.7 ± 9.42 | 102.1 ± 12.20 |
| 30 min post dose 2 (n=47,50,40) | 106.4 ± 10.32 | 102.8 ± 9.26 | 101.9 ± 9.81 |
| 60 min post dose 2 (n=46,50,37) | 107.2 ± 12.05 | 101.9 ± 11.18 | 102.9 ± 9.95 |
| 30 min post last dose (n=49,52,40) | 105.0 ± 12.22 | 101.2 ± 11.72 | 101.6 ± 12.60 |
| 60 min post last dose (n=49,52,40) | 106.1 ± 10.32 | 103.0 ± 11.87 | 104.9 ± 11.03 |
| 1.5 hours post last dose (n=48,52,40) | 104.8 ± 11.43 | 101.9 ± 11.67 | 103.0 ± 10.35 |
| 2 hours post last dose (n=50,52,40) | 104.6 ± 11.40 | 103.4 ± 10.81 | 101.8 ± 10.87 |
| 2.5 hours post last dose (n=49,52,40) | 103.0 ± 12.41 | 101.5 ± 10.58 | 101.3 ± 10.10 |
| 3 hours post last dose (n=50,52,40) | 106.1 ± 12.28 | 102.1 ± 10.84 | 101.9 ± 11.57 |
| 3.5 hours post last dose (n=50,52,40) | 103.4 ± 10.00 | 103.2 ± 11.38 | 101.4 ± 9.41 |
| 4 hours post last dose (n=50,52,40) | 103.6 ± 11.26 | 102.1 ± 10.14 | 100.5 ± 10.48 |
| 4.5 hours post last dose (n=50,52,40) | 104.5 ± 10.50 | 103.2 ± 10.96 | 101.5 ± 9.25 |
| 5 hours post last dose (n=50,52,40) | 106.7 ± 9.94 | 104.1 ± 10.46 | 102.1 ± 9.49 |
Mean systolic blood pressure measured at various timepoints minus the mean systolic blood pressure at predose
| mmHg | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| 15 min post dose 1 (n=51,52,40) | 0.8 ± 10.58 | -0.4 ± 9.57 | 2.0 ± 8.06 |
| 30 min post dose 1 (n=51,52,40) | 2.6 ± 10.14 | 0.9 ± 6.97 | -0.3 ± 7.68 |
| 60 min post dose 1 (n=51,51,40) | 3.7 ± 8.60 | 1.1 ± 9.54 | 2.6 ± 7.97 |
| 15 min post dose 2 (n=50,51,40) | 2.6 ± 8.94 | -0.3 ± 9.28 | 1.6 ± 9.07 |
| 30 min post dose 2 (n=47,50,40) | 3.3 ± 8.59 | 0.8 ± 9.01 | 1.4 ± 7.19 |
| 60 min post dose 2 (n=46,50,37) | 4.0 ± 7.89 | -0.3 ± 8.98 | 1.8 ± 8.87 |
| 30 min post last dose (n=49,52,40) | 2.4 ± 10.72 | -0.4 ± 9.37 | 1.1 ± 11.25 |
| 60 min post last dose (n=49,52,40) | 3.5 ± 10.92 | 1.5 ± 11.17 | 4.4 ± 8.43 |
| 1.5 hours post last dose (n=48,52,40) | 1.8 ± 9.70 | 0.3 ± 10.22 | 2.4 ± 8.06 |
| 2 hours post last dose (n=50,52,40) | 2.3 ± 10.31 | 1.8 ± 10.18 | 1.3 ± 9.44 |
| 2.5 hours post last dose (n=49,52,40) | 0.4 ± 10.12 | -0.0 ± 8.80 | 0.7 ± 7.77 |
| 3 hours post last dose (n=50,52,40) | 3.9 ± 10.58 | 0.6 ± 8.83 | 1.3 ± 7.28 |
| 3.5 hours post last dose (n=50,52,40) | 1.2 ± 8.87 | 1.7 ± 10.18 | 0.9 ± 7.06 |
| 4 hours post last dose (n=50,52,40) | 1.3 ± 11.08 | 0.6 ± 10.17 | -0.0 ± 8.36 |
| 4.5 hours post last dose (n=50,52,40) | 2.2 ± 10.37 | 1.7 ± 9.61 | 0.9 ± 8.26 |
| 5 hours post last dose (n=50,52,40) | 4.5 ± 10.79 | 2.5 ± 8.90 | 1.6 ± 9.62 |
Diastolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
| mmHg | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| Predose (n=51,52,40) | 62.5 ± 8.19 | 63.2 ± 6.82 | 63.6 ± 9.77 |
| 15 min post dose 1 (n=51,52,40) | 61.4 ± 9.32 | 62.0 ± 7.29 | 62.5 ± 8.52 |
| 30 min post dose 1 (n=51,52,40) | 60.8 ± 8.34 | 62.5 ± 7.61 | 61.6 ± 7.56 |
| 60 min post dose 1 (n=51,51,40) | 63.4 ± 7.72 | 62.5 ± 7.47 | 62.3 ± 9.38 |
| 15 min post dose 2 (n=50,51,40) | 61.7 ± 8.76 | 63.3 ± 6.75 | 60.8 ± 8.81 |
| 30 min post dose 2 (n=47,50,40) | 63.1 ± 7.35 | 62.2 ± 7.61 | 61.7 ± 8.86 |
| 60 min post dose 2 (n=46,50,37) | 62.8 ± 8.07 | 62.0 ± 8.15 | 62.3 ± 7.99 |
| 30 min post last dose (n=49,52,40) | 63.4 ± 7.27 | 62.0 ± 8.83 | 61.6 ± 7.91 |
| 60 min post last dose (n=49,52,40) | 63.5 ± 8.88 | 62.1 ± 8.60 | 62.5 ± 8.09 |
| 1.5 hours post last dose (n=48,52,40) | 63.1 ± 9.09 | 62.3 ± 7.90 | 62.5 ± 9.03 |
| 2 hours post last dose (n=50,52,40) | 63.8 ± 10.79 | 62.3 ± 6.87 | 62.1 ± 9.62 |
| 2.5 hours post last dose (n=49,52,40) | 60.7 ± 10.41 | 59.7 ± 7.97 | 62.3 ± 8.71 |
| 3 hours post last dose (n=50,52,40) | 63.2 ± 8.85 | 61.4 ± 7.51 | 62.5 ± 9.77 |
| 3.5 hours post last dose (n=50,52,40) | 62.0 ± 9.80 | 60.5 ± 6.54 | 62.6 ± 7.59 |
| 4 hours post last dose (n=50,52,40) | 62.9 ± 10.15 | 63.1 ± 7.32 | 59.9 ± 8.65 |
| 4.5 hours post last dose (n=50,52,40) | 62.6 ± 9.12 | 62.2 ± 7.84 | 61.9 ± 8.38 |
| 5 hours post last dose (n=50,52,40) | 62.3 ± 8.75 | 63.0 ± 7.40 | 60.0 ± 8.59 |
Mean diastolic blood pressure measured at various timepoints minus the predose diastolic blood pressure
| mmHg | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| 15 min post dose 1 (n=51,52,40) | -1.1 ± 8.60 | -1.1 ± 7.26 | -1.0 ± 10.23 |
| 30 min post dose 1 (n=51,52,40) | -1.7 ± 7.69 | -0.6 ± 7.84 | -1.9 ± 7.27 |
| 60 min post dose 1 (n=51,51,40) | 0.8 ± 7.89 | -0.7 ± 7.71 | -1.3 ± 9.43 |
| 15 min post dose 2 (n=50,51,40) | -1.1 ± 8.10 | 0.1 ± 6.85 | -2.8 ± 9.65 |
| 30 min post dose 2 (n=47,50,40) | 0.8 ± 7.82 | -1.1 ± 7.59 | -1.9 ± 9.59 |
| 60 min post dose 2 (n=46,50,37) | 0.0 ± 7.08 | -1.3 ± 6.98 | -1.8 ± 6.91 |
| 30 min post last dose (n=49,52,40) | 0.8 ± 7.12 | -1.2 ± 7.34 | -1.9 ± 9.35 |
| 60 min post last dose (n=49,52,40) | 0.8 ± 8.84 | -1.1 ± 8.48 | -1.1 ± 8.31 |
| 1.5 hours post last dose (n=48,52,40) | 0.1 ± 8.00 | -0.9 ± 7.23 | -1.1 ± 9.38 |
| 2 hours post last dose (n=50,52,40) | 1.4 ± 10.16 | -0.9 ± 7.70 | -1.5 ± 9.39 |
| 2.5 hours post last dose (n=49,52,40) | -1.9 ± 8.66 | -3.5 ± 7.36 | -1.3 ± 9.56 |
| 3 hours post last dose (n=50,52,40) | 0.8 ± 8.45 | -1.8 ± 8.31 | -1.1 ± 10.49 |
| 3.5 hours post last dose (n=50,52,40) | -0.4 ± 8.36 | -2.6 ± 6.66 | -1.0 ± 8.87 |
| 4 hours post last dose (n=50,52,40) | 0.5 ± 10.38 | -0.0 ± 7.63 | -3.7 ± 10.29 |
| 4.5 hours post last dose (n=50,52,40) | 0.2 ± 8.86 | -1.0 ± 7.64 | -1.7 ± 10.42 |
| 5 hours post last dose (n=50,52,40) | -0.1 ± 8.84 | -0.1 ± 8.06 | -3.6 ± 10.25 |
| mEq/L | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| Predose (n=51,52,39) | 4.25 ± 0.376 | 4.27 ± 0.386 | 4.31 ± 0.325 |
| 2 hours post dose 1 (n=48,47,38) | 3.67 ± 0.423 | 3.83 ± 0.391 | 3.71 ± 0.410 |
| 6 hours post dose 1 (n=48,49,38) | 3.99 ± 0.334 | 3.95 ± 0.325 | 3.87 ± 0.435 |
Change in mean serum potassium at the specified timepoint minus the predose value.
| mEq/L | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| 2 hours post dose 1 (n=48,47,38) | -0.58 ± 0.457 | -0.42 ± 0.407 | -0.62 ± 0.401 |
| 6 hours post dose 1 (n=48,49,38) | -0.23 ± 0.307 | -0.31 ± 0.450 | -0.39 ± 0.424 |
| mg/dl | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| Predose (n=51,52,40) | 86.4 ± 15.59 | 87.5 ± 15.43 | 87.6 ± 17.41 |
| 2 hours post dose 1 (n=48,47,39) | 114.5 ± 30.42 | 108.6 ± 27.51 | 120.6 ± 32.52 |
| 6 hours post dose 1 (n=49,48,38) | 107.6 ± 18.43 | 99.0 ± 15.78 | 106.3 ± 15.64 |
Change in mean serum glucose at the specified timepoint minus the predose value.
| mg/dl | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| 2 hours post dose 1 (n=48,47,39) | 27.1 ± 34.74 | 22.4 ± 32.66 | 32.9 ± 35.21 |
| 6 hours post dose 1 (n=49,48,38) | 20.3 ± 22.49 | 12.1 ± 20.59 | 18.6 ± 23.11 |
Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer. Change in FEV1 was calculated as postdose value minus the predose value at each visit.
| liters | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| 10 minutes post dose 1 (n=37,38,27) | 0.160 ± 0.102 | 0.117 ± 0.112 | 0.133 ± 0.105 |
| 25 minutes post dose 1 (n=37,37,27) | 0.159 ± 0.139 | 0.142 ± 0.151 | 0.158 ± 0.125 |
| 10 minutes post dose 2 (n=36,38,27) | 0.199 ± 0.130 | 0.169 ± 0.154 | 0.175 ± 0.106 |
| 25 minutes post dose 2 (n=36,38,27) | 0.194 ± 0.153 | 0.162 ± 0.166 | 0.183 ± 0.137 |
| 10 minutes post dose 3 (n=34,38,27) | 0.226 ± 0.144 | 0.179 ± 0.160 | 0.203 ± 0.148 |
| 25 minutes post dose 3 (n=35,38,26) | 0.226 ± 0.154 | 0.188 ± 0.150 | 0.205 ± 0.152 |
| 2 hours post dose 1 (n=36,37,27) | 0.216 ± 0.139 | 0.194 ± 0.146 | 0.218 ± 0.149 |
| 4 hours post dose 1 (n=36,38,27) | 0.163 ± 0.150 | 0.170 ± 0.175 | 0.198 ± 0.150 |
| 6 hours post dose 1 (n=36,38,27) | 0.098 ± 0.128 | 0.173 ± 0.165 | 0.174 ± 0.166 |
PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters.
| liters/second | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| predose (n=37,38,27) | 3.604 ± 0.949 | 3.546 ± 0.928 | 3.565 ± 0.675 |
| 10 minutes post dose 1 (n=37,38,27) | 3.926 ± 0.900 | 3.788 ± 0.950 | 3.824 ± 0.613 |
| 25 minutes post dose 1 (n=37,37,27) | 4.003 ± 0.893 | 3.877 ± 0.950 | 3.844 ± 0.698 |
| 10 minutes post dose 2 (n=36,38,27) | 4.053 ± 1.007 | 3.890 ± 0.998 | 3.925 ± 0.679 |
| 25 minutes post dose 2 (n=36,38,27) | 4.047 ± 0.982 | 3.964 ± 0.912 | 3.989 ± 0.652 |
| 10 minutes post dose 3 (n=34,38,27) | 4.156 ± 0.960 | 4.003 ± 0.993 | 4.077 ± 0.711 |
| 25 minutes post dose 3 (n=35,38,26) | 4.176 ± 0.966 | 4.007 ± 0.899 | 4.017 ± 0.693 |
| 2 hours post dose 1 (n=36,37,27) | 4.221 ± 0.961 | 4.178 ± 1.013 | 4.066 ± 0.668 |
| 4 hours post dose 1 (n=36,38,27) | 4.155 ± 0.984 | 4.029 ± 1.061 | 4.039 ± 0.663 |
| 6 hours post dose 1 (n=36,38,27) | 3.970 ± 0.938 | 4.058 ± 1.075 | 4.016 ± 0.628 |
PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters. Change in PEFR was calculated as postdose value minus the predose value at each visit.
| liters/second | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| 10 minutes post dose 1 (n=37,38,27) | 0.322 ± 0.305 | 0.242 ± 0.298 | 0.259 ± 0.396 |
| 25 minutes post dose 1 (n=37,37,27) | 0.399 ± 0.367 | 0.320 ± 0.392 | 0.279 ± 0.442 |
| 10 minutes post dose 2 (n=36,38,27) | 0.458 ± 0.363 | 0.344 ± 0.369 | 0.360 ± 0.406 |
| 25 minutes post dose 2 (n=36,38,27) | 0.452 ± 0.329 | 0.419 ± 0.363 | 0.424 ± 0.383 |
| 10 minutes post dose 3 (n=34,38,27) | 0.524 ± 0.343 | 0.457 ± 0.439 | 0.513 ± 0.466 |
| 25 minutes post dose 3 (n=35,38,26) | 0.539 ± 0.375 | 0.462 ± 0.429 | 0.449 ± 0.497 |
| 2 hours post dose 1 (n=36,37,27) | 0.575 ± 0.385 | 0.596 ± 0.596 | 0.501 ± 0.408 |
| 4 hours post dose 1 (n=36,38,27) | 0.509 ± 0.345 | 0.484 ± 0.440 | 0.474 ± 0.449 |
| 6 hours post dose 1 (n=36,38,27) | 0.324 ± 0.337 | 0.513 ± 0.720 | 0.451 ± 0.462 |
If the mean plasma concentration was 'below the limit of quantification' (BLQ) which was set as \<=0.5 picograms/milliliter, the value is displayed as a zero.
| picogram/milliliter | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| predose (n=51,52,39) | 0.646 ± 3.4172 | 0 ± 0.5159 | 0.737 ± 2.7612 |
| 25 minutes post dose 1 (n=50,46,36) | 2.402 ± 15.1253 | 2.236 ± 13.0128 | 1.659 ± 2.4584 |
| 25 minutes post dose 2 (n=48,47,36) | 0 ± 0.8858 | 1.845 ± 2.8085 | 3.325 ± 2.3515 |
| 2 hours post dose 1 (n=50,51,38) | 0 ± 0.0000 | 1.885 ± 1.7035 | 4.189 ± 2.8207 |
| 6 hours post dose 1 (n=50,50,37) | 0 ± 0.8899 | 0.874 ± 1.1988 | 2.818 ± 1.7195 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levalbuterol 0.63 mg | — | 0/51 (0%) | 10/51 (19.6%) |
| Arformoterol 7.5 Mcg | — | 0/52 (0%) | 7/52 (13.5%) |
| Arformoterol 15 Mcg | — | 0/40 (0%) | 8/40 (20%) |
| Event | Levalbuterol 0.63 mg | Arformoterol 7.5 Mcg | Arformoterol 15 Mcg |
|---|---|---|---|
| Urinary Tract InfectionInfections and infestations | 0/51 | 0/52 | 2/40 |
| InfluenzaInfections and infestations | 2/51 | 0/52 | 0/40 |
| NasopharyngitisInfections and infestations | 2/51 | 0/52 | 0/40 |
| Abdominal Pain UpperGastrointestinal disorders | 0/51 | 1/52 | 1/40 |
| ToothacheGastrointestinal disorders | 0/51 | 0/52 | 1/40 |
| Otitis MediaInfections and infestations | 0/51 | 0/52 | 1/40 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/51 | 0/52 | 1/40 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/51 | 0/52 | 1/40 |
| HeadacheNervous system disorders | 0/51 | 0/52 | 1/40 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/51 | 0/52 | 1/40 |
| Age, Categorical(Participants) | ARF/LEV | LEV/ARF | Total |
|---|---|---|---|
| <=18 years | 27 | 26 | 53 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | ARF/LEV | LEV/ARF | Total |
|---|---|---|---|
| Age 2-5 years | 4.4 ± 0.79 | 4.4 ± 0.79 | 4.4 ± 0.76 |
| Age 6-11 years | 9.0 ± 1.26 | 8.5 ± 1.43 | 8.8 ± 1.35 |
| Sex: Female, Male(Participants) | ARF/LEV | LEV/ARF | Total |
|---|---|---|---|
| Female | 13 | 12 | 25 |
| Male | 14 | 14 | 28 |
| Race/Ethnicity, Customized(participants) | ARF/LEV | LEV/ARF | Total |
|---|---|---|---|
| White/Caucasian | 19 | 12 | 31 |
| Black/African American | 6 | 14 | 20 |
| Other | 2 | 0 | 2 |
| Region of Enrollment(participants) | ARF/LEV | LEV/ARF | Total |
|---|---|---|---|
| United States | 27 | 26 | 53 |
| Height(centimeters) | ARF/LEV | LEV/ARF | Total |
|---|---|---|---|
| Mean | 131.62 ± 15.244 | 130.42 ± 15.377 | 131.03 ± 15.174 |
| Weight(kilograms) | ARF/LEV | LEV/ARF | Total |
|---|---|---|---|
| Mean | 31.57 ± 12.106 | 32.68 ± 12.802 | 32.12 ± 12.345 |
The record gives a start of Jan 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Formoterol · Levalbuterol
Sumitomo Pharma America, Inc. →